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Background. Lipoproteins may contribute to diabetic ne-
phropathy. Nuclear magnetic resonance (NMR) can quantify
subclasses and mean particle size of very low density lipopro-
tein (VLDL), low density lipoprotein (LDL), and high density
lipoprotein (HDL), and LDL particle concentration. The rela-
tionship between detailed lipoprotein analyses and diabetic
nephropathy is of interest.
Methods. In a cross-sectional study, lipoproteins from 428
women and 540 men from the Diabetes Control and Complica-
tions Trial/Epidemiology of Diabetes Interventions and Com-
plications (DCCT/EDIC) cohort were characterized by conven-
tional lipid enzymology, NMR, apolipoprotein levels, and LDL
oxidizibility. Linear regression was performed for each lipopro-
tein parameter versus log albumin excretion rate (AER), with
and without covariates for age, diabetes duration, HbA1c, hy-
pertension, body mass index, waist-hip ratio, and DCCT treat-
ment group. Significance was taken at P  0.05.
Results. By multivariate analysis, conventional profile, total
triglycerides, total- and LDL cholesterol, but not HDL choles-
terol, were associated with AER. NMR-determined large, me-
dium, and small VLDL were associated with AER in both gen-
ders (except large VLDL in women), and intermediate density
lipoprotein (IDL) was associated with AER (men only). LDL
particle concentration and ApoB were positively associated with
AER (in men and in the total cohort), and there was a borderline
inverse association between LDL diameter and AER in men.
Small HDL was positively associated with AER and a border-
line negative association was found for large HDL. No associa-
tions were found with ApoA1, Lp(a), or LDL oxidizibility.
Conclusion. Potentially atherogenic lipoprotein profiles are
associated with renal dysfunction in type 1 diabetes and further
details are gained from NMR analysis. Longitudinal studies
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are needed to determine if dyslipoproteinemia can predict pa-
tients at risk of nephropathy, or if lipoprotein-related interven-
tions retard nephropathy.
Diabetes is the leading cause of end-stage renal disease
in the United States [1]. In diabetes, microalbuminuria
is predictive of future proteinuria, progressive decline in
renal function, aggressive retinopathy, accelerated athero-
sclerosis, and premature mortality predominantly from
coronary artery disease [1–4]. Factors implicated in the
development of nephropathy and other micro- and macro-
vascular complications include long duration of diabetes,
poor glycemic control, smoking, and hypertension [2, 4].
Dyslipidemia has also been associated with the develop-
ment and progression of nephropathy and other vascular
complications [5–7], and lipid lowering may retard renal
damage [8].
In type 1 diabetes with good to moderate glycemic con-
trol, total and low density lipoprotein (LDL) cholesterol
and triglyceride levels are usually within the normal range.
HDL cholesterol levels are also typically normal, or even
elevated [9]. However, HDL can be subdivided into at
least 2 major subclasses, which are thought to differ in
ability to protect against atherosclerosis [10]. Appar-
ently, favorable total HDL levels may be comprised of
relatively high levels of non-cardioprotective, small HDL.
Levels of IDL may be increased, particularly in the pres-
ence of proteinuria [6], but are not readily measured.
Each major lipoprotein class is heterogeneous in size
and density [5, 6, 9–11], and subtle changes in lipopro-
teins may be relevant to the cause and to the prevention
of nephropathy and the associated accelerated athero-
sclerosis.
In this large cross-sectional study, we assessed the rela-
tionship between dyslipidemia and nephropathy in the Dia-
betes Control and Complications Trial/Epidemiology of
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Diabetes Interventions and Complications (DCCT/EDIC)
cohort of subjects with type 1 diabetes [12]. Detailed lipo-
protein analyses were performed, including a conven-
tional lipid profile, a nuclear magnetic resonance (NMR)
lipoprotein subclass profile (NMR-LSP), levels of apoli-
poprotein A1 and B (apoA1, apoB) and of lipoprotein(a)
[Lp(a)], and susceptibility of isolated LDL to oxidation.
METHODS
Study subjects
The original DCCT cohort consisted of 1441 men and
women aged 13 to 39 years with type 1 diabetes for 1 to
15 years at study entry between 1983 and 1989 [12, 13].
The study was designed to determine if intensive therapy
with the aim of maintaining blood glucose as close to
the normal range as possible would prevent or delay
long-term complications, with retinopathy being the pri-
mary end point. There were primary and secondary pre-
vention cohorts; the former consisted of 726 patients
with diabetes of 1 to 5 years’ duration who, at study
entry, had no retinopathy and urinary albumin excretion
rate (AER) 28 g/min (40 mg/24 hr). The secondary
prevention cohort consisted of 715 patients who had
had diabetes for 1 to 15 years and who had minimal-to-
moderate nonproliferative retinopathy and urinary AER
139 g/min (200 mg/24 hr). Subjects were randomly
assigned to conventional (N  730) and intensive (N 
711) diabetes treatment [12]. In 1993, after a mean fol-
low-up time of 6.5 years, the DCCT was stopped because
of major beneficial effect of intensive therapy on retinal,
renal, and neurologic complications [12]. All DCCT sub-
jects were then invited to join EDIC, an ongoing longitu-
dinal epidemiologic investigation [14]. The primary goal
of EDIC, an observational and not an interventional
study, was to study macrovascular disease in type 1 diabe-
tes, and an additional goal was to assess risk factors for
nephropathy.
Each EDIC subject annually underwent a standard-
ized history and physical examination, including a de-
tailed evaluation of overall health, diabetes management,
occurrence of diabetic complications, and medications used
[14, 15]. Hemoglobin A1c (HbA1c) was determined annu-
ally by high performance liquid chromatography (HPLC)
in the DCCT/EDIC central laboratory, as previously
described [13]. Fasting lipid profiles were also deter-
mined in the DCCT/EDIC central laboratory in alternate
years. AER and calculated creatinine clearance were
determined in the DCCT/EDIC central laboratory using
4 hour urine collections performed the same day as the
blood was drawn [14]. Retinopathy was assessed at the
annual visit alternating from the one at which the fasting
blood sample was obtained. Retinopathy was assessed
by fundus photography, and all photographs were graded
centrally according to the final Early Treatment Diabetic
Retinopathy Study (ETDRS) grading scale [16] and
DCCT methods as previously described [15].
In 1996, a collaborative project between investigators
at the Medical University of South Carolina (MUSC)
and DCCT/EDIC was implemented. Its primary goal
was to identify risk factors and mechanisms for vascular
disease in type 1 diabetes using samples shipped directly
from participating centers to MUSC. Twenty-five of the
28 DCCT/EDIC centers participated and between 1997
to 1999, fasting plasma and serum samples were sent to
MUSC. The MUSC group used these samples to deter-
mine NMR-LSP, apoA1, apoB, and Lp(a). In addition,
we isolated LDL and studied the susceptibility of its
protein (N  729) and lipid (N  726) components to
oxidative damage. Conventional lipid profiles were de-
termined by the DCCT/EDIC central laboratory (as de-
scribed below). The blood samples sent to MUSC were
obtained from the same blood drawn as the samples for
the DCCT/EDIC central laboratory.
The study was approved by the Institutional Review
Boards of MUSC and participating DCCT/EDIC centers.
Written informed consent was obtained from all partici-
pating subjects. The 968 subjects with type 1 diabetes
in whom detailed lipoprotein analyses were performed
represent 73% of the original DCCT/EDIC cohort, and
their characteristics did not differ significantly from the
entire cohort. Clinical data were obtained according to
the EDIC protocol [14, 15]. We categorized subjects into
3 groups according to AER: normal (40 mg/24 hr);
microalbuminuria (40 to 299 mg/24 hr); and albuminuria
(300 mg/24 hr). Subjects were also categorized as having
normal, elevated, or low creatinine clearance. Normal cre-
atinine clearance was considered to be 97 to 137 mL/min
for men and 88 to 128 mL/min for women [17].
Sample collection
To obtain serum, blood was collected into a Falcon tube
(Norcross, Fisher, GA, USA) containing polypropylene
beads (Sarstedt, Newton, NC, USA) by venipuncture
after an overnight fast and prior to insulin administration.
To obtain plasma for LDL preparation, 55 mL of blood
was drawn into Falcon tubes containing a lipoprotein
preservative solution comprised of 2.8 mmol/L ethylene-
diaminetetraacetic acid (EDTA), 62mol/L chloramphen-
icol, 50g/mL gentamycin sulfate, and 10 mmol/L ε-amino-
caproic-acid (final concentrations). Serum and plasma
were prepared by centrifugation (3000 rpm, 20 min), and
shipped overnight on wet ice to MUSC, where LDL was
isolated from plasma (as described below) beginning on
day of receipt, and serum [for analysis by NMR and for
apolipoproteins and Lp(a) levels] was stored at 70C
for subsequent analyses. Plasma and serum collected on
Fridays were stored at 4C until shipment to MUSC the
following Monday.
Blood samples taken at the same venipuncture were
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sent to the DCCT/EDIC Central Biochemistry Labora-
tory (CBL, Fairview University Medical Center, Univer-
sity of Minnesota) for determination of the conventional
lipid profile, HbA1c, and serum creatinine.
Conventional lipid profile
Total cholesterol was determined by a cholesterol oxi-
dase method and total triglyceride by an enzymatic
method utilizing an automated glycerol blank (Boeh-
ringer Mannheim Diagnostics, Indianapolis, IN, USA)
on a Roche Cobas Fara analyzer (Roche Diagnostics,
Indianapolis, IN, USA). HDL cholesterol was quantified
with the above cholesterol method after precipitation
of non-HDL cholesterol with magnesium/dextran. For
samples with triglycerides400 mg/dL, LDL cholesterol
was estimated by Friedewald’s formula. For samples with
triglycerides 400 mg/dL, LDL cholesterol was deter-
mined after removal of very low density lipoprotein
(VLDL) by ultracentrifugation.
NMR analysis of lipoproteins
Lipoprotein subclass levels and mean VLDL, LDL,
and HDL particle diameters were measured on freshly
thawed (0.25 mL) serum specimens using a 400 MHz
proton NMR analyzer from LipoScience, Inc. (Raleigh,
NC, USA), as previously described [18]. Spectra of each
sample were acquired in duplicate at 47C and the lipid
methyl group signal envelope at 0.8 ppm deconvoluted
to give lipoprotein subclass concentrations. Results in-
cluded levels of 6 VLDL subclasses, IDL, 3 LDL sub-
classes, 5 HDL subclasses, mean diameter of VLDL, LDL,
and HDL, and LDL particle concentration. NMR con-
vention is that larger subclass descriptor numbers denote
larger particles. Data for VLDL and HDL subclasses sug-
gested that subclass regrouping was appropriate to sim-
plify data analysis. For data analysis, VLDL subclasses
were regrouped as large (V6, V5), medium (V4, V3), and
small (V2, V1) subclasses, and HDL subclasses as large
(cardioprotective H5, H4, H3) and small (non-cardiopro-
tective H2, H1) subclasses. The subclass designations and
their approximate diameter (nm) ranges, determined by
calibration using purified subfractions analyzed by elec-
tron microscopy (VLDL and LDL), or polyacrylamide
gradient gel electrophoresis (HDL), are as shown in Fig-
ure 1. The IDL and LDL subclass diameters, which are
uniformly 5 nm smaller than those estimated by gradi-
ent gel electrophoresis, are consistent with both electron
microscopy and lipid compositional data [18].
Bulk lipid mass concentrations of chylomicrons and
VLDL subclasses (V1 to V6) are reported in units of
triglyceride (mg/dL) and those of IDL, LDL (L1 to L3),
and HDL (H1 to H5) subclasses in units of cholesterol
(mg/dL). Average VLDL, LDL, and HDL particle sizes
(nm diameter) were determined by weighing the relative
mass percentage of each subclass by its diameter. LDL
Fig. 1. Nuclear magnetic resonance (NMR)-derived subclasses and li-
poprotein particle sizes.
particle concentrations (nmol/L) are the sums of the
particle concentrations of the individual LDL subclasses.
Analysis of fresh and previously frozen serum from
379 subjects from the general population demonstrated
lack of significant effect of a single freeze thaw cycle on
the NMR spectra of serum. Acute glucose addition to
nondiabetic sera and nonenzymatic glycation of lipopro-
teins isolated by sequential ultracentrifugation from non-
diabetic subjects did not alter the NMR spectra [abstract;
Lyons TJ et al, Diabetes 49(Suppl 1):1117P, 2000].
Apolipoproteins and Lp(a) levels
Nephelometric assays (Beckman, Brea, CA, USA)
were used according to the manufacturer’s instructions
to determine serum ApoA1, ApoB, and Lp(a).
LDL oxidizibility
LDL (d  1.019 to 1.063 g/mL) was isolated from
plasma by sequential ultracentrifugation. Oxidizibility of
the lipid component of LDL was determined by modifi-
cation of the method of Esterbauer, as described [19].
Briefly, EDTA was removed from LDL by size exclusion
chromatography on Sephadex G-25 columns, diluted to
100 g/mL cholesterol, and exposed to Cu ions (final
concentration 5 mol/L) at 30C. Results are expressed
as the change in absorbance (	 absorbance) at 234 nm
from baseline to peak absorbance (reflecting conjugated
diene formation). Oxidizibility of the protein component
was determined in the same sample from the develop-
ment of fluorescence (Ex 360 nm/Em 430 nm) under the
same conditions, expressed as the ratio of fluorescence
at 24 hours’ exposure to Cu to baseline fluorescence.
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Table 1. Clinical characteristics of Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) study subjects at time of sample acquisition
Women (N  425) Men (N  533)
Intensive Conventional Intensive Conventional
(N  222) (N  203) (N  270) (N  263)
Mean (SE) Mean (SE) P Mean (SE) Mean (SE) P
Age years 39.9 (0.5) 38.4 (0.5) 0.05 39.9 (0.4) 40.2 (0.4) NS
Duration of type 1 diabetes years 17.6 (0.3) 17.8 (0.4) NS 17.5 (0.3) 16.8 (0.3) NS
Body mass index kg/m2 26.8 (0.3) 25.9 (0.3) 0.05 27.3 (0.3) 27.0 (0.2) NS
Waist-to-hip ratio 0.8 (0.0) 0.8 (0.0) NS 0.9 (0.0) 0.9 (0.0) NS
Current HbA1c % hemoglobin 8.2 (0.1) 8.2 (0.1) NS 8.1 (0.1) 8.3 (0.1) 0.05
Mean HbA1c during DCCT % hemoglobin 7.3 (0.1) 9.1 (0.1) 0.0001 7.2 (0.1) 9.0 (0.1) 0.0001
Systolic blood pressure mm Hg 116.9 (1.0) 115.0 (0.9) NS 121.1 (0.7) 123.6 (0.9) 0.05
Diastolic blood pressure mm Hg 73.3 (0.6) 72.2 (0.6) NS 76.4 (0.5) 77.3 (0.6) NS
Total cholesterol mg/dL 189.0 (2.2) 187.1 (2.3) NS 190.0 (2.2) 188.7 (2.2) NS
HDL (conventional profile; chol.) mg/dL 63.0 (1.0) 62.7 (1.0) NS 51.2 (0.8) 51.7 (0.7) NS
LDL (conventional profile; chol.) mg/dL 110.9 (2.0) 108.8 (2.1) NS 118.8 (1.9) 118.1 (1.9) NS
Triglycerides (conventional profile) mg/dL 75.7 (2.5) 78.0 (4.0) NS 98.2 (4.1) 96.2 (4.5) NS
Log albumin excretion rate mg/24 hours 2.3 (0.1) 2.6 (0.1) 0.003 2.5 (0.1) 3.0 (0.1) 0.001
Albumin excretion rate mg/24hours 49.3 (27.7) 74.0 (28.9) NS 92.2 (43.7) 159.7 (44.3) NS
Standard creatinine clearance mL/min 110.9 (1.6) 110.3 (1.7) NS 120.6 (1.4) 119.2 (1.6) NS
ETDRS score 3.2 (0.2) 5.3 (0.3) 0.0001 3.7 (0.2) 5.7 (0.2) 0.0001
% (SE) % (SE) P % (SE) % (SE) P
% Body mass index 27.3 in women, 27.8 in men kg/m2 39.3 (0.2) 28.2 (0.6) 0.02 38.5 (0.2) 36.3 (0.5) NS
% Hypertensiona 26.1 (0.2) 26.2 (0.6) NS 42.1 (0.2) 47.3 (0.5) NS
% Albumin excretion ratio 40 mg/24 hours 6.8 (0.1) 16.8 (0.5) 0.001 11.5 (0.1) 20.5 (0.4) 0.005
% Current smoker 20.9 (0.2) 17.3 (0.5) NS 20.3 (0.1) 18.3 (0.4) NS
% Taking lipid-lowering medications 4.0 (0.1) 3.9 (0.3) NS 7.3 (0.1) 6.0 (0.2) NS
% Taking ACE inhibitor 6.7 (0.1) 13.8 (0.5) 0.02 12.4 (0.1) 17.7 (0.4) NS
Abbreviations are: ACE, angiotensin-converting enzyme; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c.
a Hypertension is defined by previously documented or current systolic blood pressure/diastolic blood pressure equal or greater than 140/90 mm Hg
Statistical analyses
Descriptive data in Tables 1 through 7 are mean [stan-
dard error of the mean (SE)]. For the analyses examining
differences between treatment groups (Table 1), we used
a two-sample t test assuming equal variances or a chi-
square test (1 d.f.). For the analyses examining differ-
ences between the 3 AER or creatinine clearance groups
as a categorical variable (Table 2), we used a multivariate
analysis of variance (MANOVA) assuming equal vari-
ances or a chi-square test. To examine whether lipopro-
tein-related parameters predicted trends in AER, we
treated log-transformed AER as a continuous dependent
variable in 3 regressions. In the first, only the lipoprotein-
related parameter was included as an independent vari-
able in the model. In the second, a standard set of covari-
ates (obtained concurrently with sample collection) was
added, including age, diabetes duration, HbA1c, hyper-
tension, body mass index, waist-hip ratio, and DCCT
randomization group. These analyses were done sepa-
rately for women, men, and both genders combined.
When the analysis was conducted for the total group,
gender was included as an additional independent vari-
able in the model. In the third regression, we tested for
interactions between the specified lipoprotein parameter
and gender using the same set of covariates (i.e., to assess
whether the relationship between the lipoprotein-related
parameter and renal status was the same for males and
females). Similar analyses were performed with creati-
nine clearance replacing AER as the dependent variable.
RESULTS
Table 1 presents clinical characteristics of the subjects
in whom detailed lipoprotein profiles were obtained, ac-
cording to gender and former DCCT randomization.
Significant differences between the original DCCT inten-
sive and conventional treatment groups are demonstrated
for nephropathy and retinopathy status, as described re-
cently for the entire cohort [15]. For AER, the difference
was significant when AER was considered as a continu-
ous variable or as a categorical variable (40 or 40 mg/
24 hr). There is also a persisting difference in current
HbA1c between prior DCCT treatment groups for men,
although this is small compared with the difference that
was maintained (for both genders) during the DCCT
[12]. Additionally, women in the former intensive man-
agement group were significantly heavier than women
in the former conventional management group, and less
likely to be taking angiotensin-converting enzyme (ACE)
inhibitors; neither of these differences was significant for
male participants. Plasma lipid profiles and serum NMR-
LSP (not shown in Table 1) did not differ between sub-
jects (of either gender) grouped according to prior DCCT
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Table 2. Clinical characteristics of Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications
(DCCT/EDIC) study by albumin excretion rate (AER) status
Reference MA vs. no MA MA vs. Alb Alb vs. no MA
range AER 40 AER 40–299 AER 300 P P P
Women/men 376/448 37/55 12/30 0.05 NS NS
Age years — 39.7 (0.2) 38.9 (0.8) 40.19 (1.2) NS NS NS
Diabetes duration years — 17.2 (0.2) 18.2 (0.5) 19.6 (0.7) 0.01 NS 0.06
DCCT group % standard/intensive 46/54 60/40 79/21 0.0001 0.05 0.05
High body mass index (BMI) %a — 36 41 29 NS NS NS
High waist to hip ratio (WHR) %b — 27 34 40 0.06 NS NS
Current HbA1c % 6.0 8.1 (0.1) 8.9 (0.2) 8.9 (0.2) 0.0001 NS 0.0001
Mean HbA1c in DCCT % — 7.9 (0.1) 8.9 (0.2) 9.8 (0.2) 0.0001 0.001 0.0001
Systolic blood pressure mm Hg 135 118 (0.5) 122 (1.6) 135 (20) 0.0001 0.001 0.05
Diastolic blood pressure mm Hg 85 75 (0.3) 77 (1.2) 80 (3.1) 0.001 NS 0.05
Hypertension %c — 33 49 88 0.0001 0.0001 0.01
Taking antihypertensive agents % — 10 32 76 0.0001 0.0001 0.0001
Serum creatinine mg/dL 0.7–1.2 0.9 (0.0) 0.9 (0.0) 1.3 (0.1) 0.001 0.001 NS
Serum blood urea nitrogen mg/dL 7–17 13.9 (0.1) 14.7 (0.4) 21.6 (1.7) 0.0001 0.001 0.06
Creatinine clearance mL/min 80–125 116 (0.8) 127 (3.1) 98 (5.8) 0.01 0.0001 0.01
% on ACE Inhibitorsd — 8 28 64 0.0001 0.0001 0.0001
Retinopathy % mild/moderate/severee 55/40/5 22/54/24 7/56/37 0.0001 0.08 0.0001
% on lipid lowering drugs — 5 8 17 0.001 NS NS
Smokers % — 18 29 29 0.08 NS 0.05
HbA1c is hemoglobin A1c.
a High BMI, 27.8 for males; 27.3 for females
b High WHR, 0.90 for males; 0.85 for females
c Hypertension  blood pressure 140/90 or previously documented hypertension
d ACE (angiotensin-converting enzyme) inhibitors (or angiotensin receptor antagonists)
e Retinopathy status: defined by ETDRS scores: mild, 1–3; moderate: 4–9; severe: 10–23
treatment. However, lipids and the NMR-LSP differed
substantially between genders [20], and for this reason
data for men and women were analyzed separately.
Table 2 presents clinical characteristics of study sub-
jects according to AER status. Compared with subjects
with normal AER, those with increased AER were more
likely to have been randomized to conventional treat-
ment during the DCCT, to be male, and to smoke. Sub-
jects with elevated AER had longer diabetes duration,
higher blood pressure, more severe retinopathy, higher
current HbA1c, and were more likely to be receiving
anti-hypertensive or lipid-lowering drugs.
Tables 3 through 6 relate lipoprotein-related parame-
ters to AER. Results are given with AER as a categorical
variable (normoalbuminuria,40 mg/24 hr), microalbu-
minuria (40 to 299 mg/24 hr) and albuminuria (300
mg/24 hr). Also shown are results of regression analyses
that relate each lipoprotein-related parameter (as the in-
dependent variable) to log AER analyzed as a continuous
variable. Three different regression analyses are reported:
p1 refers to a univariate (raw data) analysis; p2 refers to
a multivariate regression with age, (gender for the total
cohort), diabetes duration, hypertension, HbA1c, BMI,
WHR, and DCCT randomization group as covariates;
p3 refers to interactions between the lipoprotein-related
parameter and gender, with the same covariates as p2.
Table 3 presents results for the conventional lipid pro-
file. In the multivariate analysis, triglycerides, total and
LDL cholesterol are significantly related to AER in
women, men, and the total cohort. HDL cholesterol was
not associated with AER. There were no significant gen-
der interactions with these parameters.
Tables 4 and 5 present NMR-LSP results. Table 4
summarizes data for the individual lipoprotein subclasses.
Many of the NMR-determined parameters were associ-
ated with (log) AER (analyzed as a continuous variable)
by univariate analysis, but we will emphasize results of
the multivariate analysis in order to identify independent
associations. In multivariate analysis, large VLDL was
associated with AER in men and the total cohort, and
medium and small VLDL were strongly associated with
men and women. IDL was associated with AER in men
only. None of the LDL subclasses was associated with
AER. Nevertheless, as shown in Table 4, in men, the
LDL subclass peak shifts with increasing AER; in the
presence of normal AER the major LDL peak is L3, in
microalbuminuria it is L2, and in albuminuria it is the
smallest, L1. For the 2 HDL subclasses, small HDL was
positively associated with AER in men and the total
cohort, while large HDL exhibited a borderline negative
association in the total cohort.
Table 5 presents data for the NMR-derived mean par-
ticle size (for VLDL, LDL, and HDL) and LDL particle
concentration. In multivariate analysis in men, there was
an inverse association between LDL diameter and AER,
indicative of a shift from large to smaller LDL particles
with increasing AER. In men and the total cohort there
was also observed a significant positive association be-
tween LDL particle concentration and AER.
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Table 3. Standard lipid profile in sera from women and men from the Diabetes Control and Complications Trial/Epidemiology of Diabetes
Interventions and Complications (DCCT/EDIC) cohort
Albumin excretion rate (AER) mg/24 hours
Significance40 40–299 300
Conventional lipid (393 females, 454 males, (42 females, 58 males, (14 females, 36 males,
profile mg/dL total 847) Mean (SE) total 100) Mean (SE) total 50) Mean (SE) P 1 P 2 P 3
Total cholesterol
Female 186.9 (1.7) 190.7 (5.1) 218.4 (8.9) 0.002 0.03
Male 187.3 (1.7) 192.6 (4.7) 210.6 (6.0) 0.0001 0.0010
Total 187.1 (1.2) 191.8 (3.5) 212.8 (4.9) 0.0001 0.0001 NS
Total triglycerides
Female 72.9 (2.2) 92.9 (7.0) 126.1 (25.2) 0.0001 0.01
Male 94.0 (3.3) 94.7 (6.2) 147.9 (12.9) 0.0001 0.01
Total 84.4 (2.1) 94.0 (4.6) 141.5 (11.6) 0.0001 0.0001 NS
LDL cholesterol
Female 108.2 (1.4) 115.6 (5.2) 135.6 (7.9) 0.002 0.05
Male 116.7 (1.4) 123.6 (4.0) 133.1 (6.0) 0.002 0.02
Total 112.9 (1.0) 120.3 (3.2) 133.8 (4.8) 0.0001 0.002 NS
HDL cholesterol
Female 63.2 (0.7) 58.3 (2.3) 65.8 (4.0) 0.04 NS
Male 51.5 (0.6) 50.3 (1.8) 52.2 (2.3) NS NS
Total 56.8 (0.5) 53.6 (1.5) 56.2 (2.2) 0.005 NS NS
Abbreviations are: LDL, low-density lipoprotein; HDL, high-density lipoprotein.
P 1 test for trend, dependent variable is log AER, independent variable is specified lipid.
P 2 test for trend, dependent variable is log AER, independent parameter adjusted age, (gender for total cohort), diabetes duration, hypertension, HbA1c, BMI,
WHR, and DCCT randomization group.
P 3 test for interaction between specified lipid parameter and gender; covariates as for P 2.
Table 6 presents the results of the association between
AER and apolipoprotein and Lp(a) levels and LDL oxi-
dizibility. Among this set of determinations, only ApoB
in men and in the whole cohort was significantly associ-
ated with AER by multivariate analysis. In men only,
there was a borderline association of ApoA1 with AER.
No associations were observed with levels of Lp(a) or
log Lp(a) (data not shown), or with the oxidizibility of
the protein or lipid components of isolated LDL in either
gender or the combined groups.
We also analyzed our data to determine whether lipo-
protein parameters were associated with creatinine clear-
ance. For this analysis, subjects were categorized as having
normal, elevated, or low creatinine clearance. Normal
creatinine clearance was considered to be 97 to 137 mL/
min for men, and 88 to 128 mL/min for women [17] (total
cohort data shown in Table 7). In regression analyses
(as for AER), creatinine clearance was analyzed as a
continuous variable. Associations were generally similar
to that of AER. Using the same covariates as listed
above, the following lipoprotein parameters were found
to be significantly associated (P  0.05) with worsening
nephropathy as assessed by creatinine clearance: women,
conventional profile, triglycerides; NMR-LSP: medium
and small VLDL; ApoB, ApoA1; men, conventional
profile, no associations; NMR-LSP: small VLDL, small
LDL, LDL size (inverse), LDL particle concentration;
ApoB (data not shown); total cohort, conventional pro-
file, triglycerides; NMR-LSP: large VLDL, small VLDL,
small LDL, LDL size (inverse), and LDL particle con-
centration; ApoB, ApoA1.
DISCUSSION
We conducted detailed lipoprotein analyses, including
enzymatic lipid assays, NMR lipoprotein profiles, and
apolipoprotein measures in serum and LDL oxidizibility,
in a representative subset of the DCCT/EDIC cohort of
subjects with type 1 diabetes. Nephropathy was indepen-
dently associated with an adverse lipoprotein profile,
which differed between men and women, and resembled
that related to insulin resistance and cardiovascular dis-
ease. In general, renal dysfunction was associated with
elevated triglyceride rich lipoprotein subclasses, a shift
toward small LDL particles and small HDL subclasses.
HDL-cholesterol, ApoA1 and Lp(a) levels, and the sus-
ceptibility of LDL to in vitro oxidation were not related
to nephropathy.
Intensive diabetes management, as during the DCCT,
is associated with better glycemic control, and also with
significantly lower triglycerides, LDL cholesterol, and
ApoB [21]. This observation, and data from cross-sec-
tional and some prospective studies [5, 7, 22, 23], is in
keeping with dyslipidemia-promoting diabetic nephrop-
athy. Mitigating this dyslipidemia may have conferred
some of the still evident renal benefits of intensive diabe-
tes management in the DCCT.
The DCCT/EDIC cohort is a large and well-character-
ized type 1 diabetes cohort, with an ongoing accumula-
tion of clinical, biochemical, and genetic data. The cohort
was studied at a time when the difference in HbA1c
between former DCCT randomization groups that in-
fluenced the lipoprotein profile [20] had almost disap-
peared. By employing the novel NMR technique, which
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Table 4. Nuclear magnetic resonance (NMR) determined lipoprotein subclasses in sera in women and men from the Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort
Albumin excretion rate (AER) mg/24hours
Significance40 40–299 300
NMR lipoprotein (376 females, 448 males, (37 females, 55 males, (12 females, 30 males,
subclass mg/dL total 824) Mean (SE) total 92) Mean (SE) total 42) Mean (SE) P 1 P 2 P 3
Large VDL
Female 5.5 (0.7) 9.3 (2.3) 9.8 (3.6) NS NS
Male 11.7 (1.3) 11.4 (3.1) 28.5 (10.0) 0.001 0.05
Total 8.9 (0.8) 10.6 (2.1) 23.2 (7.3) 0.0001 0.001 NS
Medium VLDL
Female 14.0 (1.0) 22.7 (3.9) 38.7 (15.5) 0.0001 0.0005
Male 29.1 (1.8) 30.8 (4.0) 51.5 (8.9) 0.001 0.02
Total 22.2 (1.1) 27.5 (2.9) 47.8 (7.7) 0.0001 0.0005 NS
Small VLDL
Female 14.6 (0.7) 21.5 (3.1) 34.6 (9.0) 0.0001 0.0005
Male 20.8 (0.7) 26.4 (2.4) 34.6 (4.7) 0.0001 0.0001
Total 18.0 (0.5) 24.4 (1.9) 34.6 (4.2) 0.0001 0.0001 NS
IDL
Female 2.3 (0.2) 2.1 (0.7) 2.0 (1.6) NS NS
Male 1.4 (0.2) 0.6 (0.2) 4.2 (1.4) 0.005 0.01
Total 1.8 (0.1) 1.2 (0.3) 3.6 (1.1) NS NS 0.005
L3
Female 69.1 (1.8) 62.5 (6.6) 90.5 (11.2) NS NS
Male 56.1 (1.9) 48.7 (5.0) 48.3 (7.2) NS NS
Total 62.0 (1.3) 54.2 (4.0) 60.4 (6.7) NS NS NS
L2
Female 28.9 (1.7) 41.4 (6.9) 28.4 (7.4) 0.05 NS
Male 41.3 (1.7) 55.3 (5.3) 32.7 (7.0) NS NS
Total 35.6 (1.2) 49.7 (4.2) 31.5 (5.4) 0.02 NS NS
L1
Female 26.4 (1.4) 22.5 (5.4) 29.7 (12.4) NS NS
Male 30.4 (1.7) 28.2 (4.5) 56.3 (8.1) 0.002 NS
Total 28.6 (1.1) 25.9 (3.5) 48.7 (7.0) 0.005 NS 0.05
Large HDL
Female 43.1 (0.7) 37.5 (2.8) 41.4 (4.3) 0.02 NS
Male 29.5 (0.7) 27.0 (1.8) 24.3 (2.8) 0.05 NS
Total 35.7 (0.6) 31.2 (1.6) 29.2 (2.6) 0.0001 0.05 NS
Small HDL
Female 14.4 (0.3) 16.4 (1.1) 18.2 (1.6) 0.005 NS
Male 19.6 (0.3) 20.9 (0.8) 22.7 (1.2) 0.02 0.05
Total 17.2 (0.2) 19.1 (0.7) 21.4 (1.0) 0.0001 0.01 NS
Abbreviations are: HbA1c, hemoglobin A1c; BMI, body mass index; WHR, waist to hip ratio; VLDL, very low-density lipoprotein; IDL, intermediate-density
lipoprotein; HDL, high-density lipoprotein.
P 1 test for trend, dependent variable is log AER, independent variable is specified lipid.
P 2 test for trend, dependent variable is log AER, independent parameter adjusted age, (gender for total cohort), duration of diabetes, hypertension, HbA1c, BMI,
WHR, and DCCT randomization group.
P 3 test for interaction between specified lipid parameter and gender; covariates as for P 2.
is highly efficient in terms of time, labor, sample volume,
and cost, we have been able to define in great detail the
associations between lipoproteins and nephropathy status,
and to relate findings with this novel technique to other
lipoprotein assessment techniques. Numerous potentially
pro-atherogenic and insulin resistance–related associations
between lipoprotein-related parameters and nephropa-
thy were observed. These associations were generally
strongest in univariate analyses, but as other parameters,
such as glycemia and body habitus, may influence or be
strongly associated with lipoproteins, we will emphasize
results of the more rigorous multivariate analyses.
In the conventional lipid profile, total triglyceride, to-
tal- and LDL cholesterol levels were associated with
AER in both genders, in agreement with the earlier
literature [6, 24]. In contrast, HDL cholesterol was not
associated with AER. Regarding the relationship be-
tween total triglycerides and AER, NMR-LSP revealed
that this is attributable to increases in all 3 VLDL sub-
classes in men, and medium and small VLDL in women.
For women, no other lipoprotein parameters were inde-
pendently associated with AER. Specifically, despite the
association of conventional (calculated) LDL-choles-
terol with AER, none of the individual LDL subclasses
was related to nephropathy. In contrast, for men, multi-
ple associations with lipoprotein subclasses were observed;
IDL, LDL particle concentration, small (non-cardiopro-
tective) HDL, and ApoB were all associated with AER,
and LDL particle diameter exhibited a borderline inverse
association. Also in men, but not in women, shifts in the
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Table 5. Nuclear magnetic resonance (NMR) determined mean lipoprotein particle diameter in women and men from the Diabetes Control
and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort
Albumin excretion rate (AER) mg/24hours
Significance40 40–299 300
NMR particle size and (376 females, 448 males, (37 females, 55 males, (12 females, 30 males,
LDL concentration total 824) Mean (SE) total 92) Mean (SE) total 42) Mean (SE) P 1 P 2 P 3
VLDL size nm
Female 52.6 (1.1) 48.1 (1.9) 47.0 (3.4) NS NS
Male 48.4 (0.7) 45.0 (1.0) 46.3 (1.9) NS NS
Total 50.3 (0.6) 46.3 (1.0) 46.5 (1.6) NS NS NS
LDL size nm
Female 21.0 (0.0) 21.0 (0.1) 21.2 (0.2) NS NS
Male 20.8 (0.0) 20.7 (0.1) 20.4 (0.1) 0.002 0.06
Total 20.9 (0.0) 20.9 (0.1) 20.6 (0.1) 0.002 NS NS
HDL size nm
Female 9.3 (0.0) 9.1 (0.1) 9.2 (0.1) 0.05 NS
Male 8.9 (0.0) 8.8 (0.1) 8.7 (0.1) 0.02 NS
Total 9.0 (0.0) 8.9 (0.0) 8.8 (0.1) 0.0001 NS NS
LDL particle concentration nmol/L
Female 1407 (19) 1413 (78) 1660 (146) 0.05 NS
Male 1461 (20) 1496 (49) 1707 (91) 0.005 0.05
Total 1436 (14) 1463 (43) 1694 (77) 0.0001 0.05 NS
Abbreviations are: VLDL, very low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; BMI, body mass
index; WHR, waist to hip ratio.
P 1 test for trend, dependent variable is log AER, independent variable is specified lipid.
P 2 test for trend, dependent variable is log AER, independent parameter adjusted age, (gender for total cohort), duration of diabetes, hypertension, HbA1c, BMI,
WHR, and DCCT randomization group.
P 3 test for interaction between specified lipid parameter and gender; covariates as for P 2.
Table 6. Apolipoproteins and lipoprotein (a) [Lp(a)] levels in sera and low-density lipoprotein (LDL) oxidizibility in women and men from
the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort
Albumin excretion rate (AER) mg/24hours
Significance40 40–299 300
Apolipoproteins, lipoprotein(a),
LDL oxidizibility N Mean (SE) N Mean (SE) N Mean (SE) P 1 P 2 P 3
ApoB mg/dL
Female 393 82 (1.2) 39 88 (4.7) 13 102 (8.0) 0.005 0.07
Male 460 90 (1.2) 58 96 (3.0) 34 105 (4.5) 0.0001 0.01
Total 853 87 (0.9) 97 93 (2.6) 47 104 (3.9) 0.0001 0.002 NS
ApoA1 mg/dL
Female 393 148 (1.6) 39 143 (5.4) 13 158 (8.1) NS NS
Male 461 137 (1.3) 58 136 (3.3) 34 151 (6.0) 0.02 0.06
Total 854 142 (1.0) 97 139 (2.9) 47 153 (4.8) NS 0.10 NS
Lp(a) mg/dL
Female 392 24 (1.4) 39 27 (5.3) 13 20 (4.9) NS NS
Male 459 22 (1.3) 56 21 (3.3) 34 22 (5.1) NS NS
Total 851 23 (0.9) 95 24 (2.9) 47 22 (3.8) NS NS NS
LDL fluorescence ratio
Female 291 7.1 (0.2) 26 6.0 (0.5) 9 5.9 (1.0) NS NS
Male 323 6.9 (0.2) 43 6.9 (0.6) 27 5.9 (0.3) NS NS
Total 614 7.0 (0.2) 69 6.6 (0.4) 36 5.9 (0.3) NS NS NS
LDL delta absorbance
Female 285 1.2 (0.0) 26 1.2 (0.1) 9 1.3 (0.1) NS NS
Male 322 1.1 (0.0) 43 1.1 (0.0) 26 1.2 (0.1) NS NS
Total 607 1.1 (0.0) 69 1.2 (0.0) 35 1.2 (0.1) NS NS NS
Abbreviations are: ApoB, apolipoprotein B; ApoA1, apoprotein A1; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; BMI, body mass index; WHR, waist
to hip ratio.
P 1 test for trend, dependent variable is log AER, independent variable is specified lipoprotein-related parameter.
P 2 test for trend, dependent variable is log AER, independent parameter adjusted age, (gender for total cohort), duration of diabetes, hypertension, HbA1c, BMI,
WHR, and DCCT randomization group.
P 3 test for interaction between specified lipid parameter and gender; covariates as for P 2.
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Table 7. Lipoprotein related parameters as a function of normal, elevated, and low creatinine clearance
Normal Elevated Low Significance
Variable N Mean (SE) N Mean (SE) N Mean (SE) P 1 P 2 P 3
Conventional lipid
Total cholesterol 666 187.3 (1.4) 201 188.3 (2.5) 201 197.8 (3.0) 0.05 NS NS
Triglyceride 666 85.7 (2.3) 201 83.3 (3.9) 132 108.5 (6.7) 0.002 0.01 0.005
LDL-cholesterol 662 114.0 (1.2) 201 115.3 (2.1) 131 118.7 (2.9) NS NS NS
HDL-cholesterol 666 56.2 (0.6) 201 56.3 (1.0) 132 57.4 (1.3) NS NS NS
Nuclear magnetic resonance
Large VLDL 642 8.5 (0.9) 186 10.5 (1.5) 130 13.6 (2.8) 0.05 0.05 NS
Medium VLDL 642 23.7 (1.3) 186 20.0 (1.9) 130 30.7 (3.4) NS NS 0.005
Small VLDL 642 18.7 (0.6) 186 18.2 (1.1) 130 25.1 (1.9) 0.0005 0.0005 NS
IDL 642 1.7 (0.1) 186 1.7 (0.3) 130 2.6 (0.4) 0.035 0.05 NS
L3 642 62.1 (1.5) 186 59.3 (2.8) 130 59.3 (3.3) NS NS NS
L2 642 36.1 (1.4) 186 42.8 (2.6) 130 32.6 (3.2) NS NS NS
L1 642 27.1 (1.2) 186 28.1 (2.5) 130 40.6 (3.7) 0.0002 0.001 NS
Large HDL 642 34.7 (0.6) 186 35.9 (1.2) 130 34.5 (1.6) NS NS NS
Small HDL 642 17.5 (0.3) 186 17.3 (0.5) 130 18.5 (0.7) NS NS NS
VLDL size 642 49.4 (0.7) 186 52.7 (1.3) 130 47.0 (1.0) NS NS NS
LDL size 642 20.9 (0.0) 186 20.9 (0.0) 130 20.8 (0.1) 0.01 0.01 NS
HDL size 642 9.0 (0.0) 186 9.0 (0.0) 130 9.0 (0.0) NS NS NS
LDL particle concentration 642 1419 (15) 186 1477 (30) 130 1565 (43) 0.0002 0.0005 NS
Others
ApoB 665 86 (1.0) 198 89 (1.8) 136 95 (2.5) 0.0005 0.0005 NS
ApoA1 666 141 (1.1) 198 142 (2.4) 136 148 (2.5) 0.02 0.02 NS
Lp(a) 666 2.5 (0.0) 195 2.5 (0.1) 134 2.5 (0.1) NS NS NS
LDL fluorescence ratio 469 6.9 (0.2) 151 6.5 (0.3) 103 7.4 (0.4) NS NS NS
LDL delta absorbance 464 1.2 (0.0) 149 1.1 (0.0) 103 1.2 (0.0) NS NS NS
Abbreviations are: LDL, low-density lipoprotein; HDL, high-density lipoprotein; VLDL, very low-density lipoprotein; IDL, intermediate-density lipoprotein;
ApoB, apolipoprotein B; ApoA1, apoprotein A1; Lp(a), lipoprotein (a); HbA1c, hemoglobin A1c; BMI, body mass index; WHR, waist to hip ratio.
P 1 test for trend, dependent variable is creatinine clearance, independent variable is specified lipoprotein-related parameter.
P 2 test for trend, dependent variable is creatinine clearance, independent is specified lipid parameter, adjusted age, gender, duration of diabetes, hypertension,
HbA1c, BMI, WHR, and DCCT randomization group.
P 3 test for interaction between specified lipid parameter and gender; covariates as for P 2.
proportion of large:small LDL (L3:L1) and large:small
HDL were observed as AER increased. These shifts
were toward a more atherogenic lipoprotein profile (i.e.,
a higher proportion of smaller LDL and smaller HDL
particles). The greater association of lipid parameters
and AER in men than in women may contribute to the
higher susceptibility of men to nephropathy [25, 26].
The men in our cohort have significantly less favorable
lipoprotein profiles than women, and had higher AER
[20] (Table 1).
With respect to nephropathy, the NMR lipoprotein
analysis provided additional information to that gained
from the conventional lipid profile. While the findings
from NMR-LSP in relation to VLDL subclasses essen-
tially confirmed the association observed with total tri-
glyceride in the conventional lipid profile, the findings
relating to IDL levels, LDL particle concentration, shifts
in LDL size, and small HDL in men could not be dis-
cerned from the conventional profile. IDL is not mea-
sured in the conventional analysis, and consistent with
our findings, Sibley et al [6], using density gradient ultra-
centrifugation in a cross-sectional analysis of the DCCT
cohort at close-out, demonstrated increased IDL choles-
terol in microalbuminuric and albuminuric subjects com-
pared with normoalbuminuric subjects. Winocour et al
[27] and Groop et al [28] also demonstrated increased
IDL in cross-sectional studies of micro- versus normo-
albuminuric subjects with type 1 diabetes. For LDL, our
finding of a shift toward smaller particles with increasing
AER supports the findings of Sibley et al [6], but not
those of Lahdenpera et al [5], who found no association
between LDL density distribution and AER in type 1
diabetes. Concerning HDL, a 10-year prospective study
predominantly of subjects with type 1 diabetes identified
low HDL cholesterol as a risk factor for renal disease
[23], but HDL subclasses were not assessed. The lack of
a relationship between enzymatic HDL cholesterol levels
and AER in the current study can be explained by the
fact that large and small HDL subclasses had an opposite
association with nephropathy.
ApoB, which is present on VLDL, LDL, IDL, and
Lp(a), was associated with AER in men and in the entire
cohort. In a cross-sectional study Attman et al [29] also
demonstrated higher ApoB levels in subjects with type 1
diabetes with nephropathy relative to nephropathy-free
type 1 diabetic subjects and healthy controls. Elevated
ApoB confers an increased risk of coronary disease, and,
consistent with our findings in the present study, has been
associated with an accelerated decline in glomerular fil-
tration rate in type 1 diabetic subjects with nephropathy
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[30]. Using immunoprecipitation techniques, Samuelsson
et al [7] and Attman et al [8] revealed that the association
of ApoB with the rate of progression of (nondiabetic)
renal disease could be attributed to the triglyceride-rich
apoB-containing lipoproteins, and that cholesterol-rich
ApoB-containing lipoproteins, including LDL, were not
implicated. These data are consistent with our finding that
NMR-determined VLDL subclasses are more strongly
associated with AER than LDL subclasses.
For ApoA1, we found borderline (P  0.06) positive
associations with AER in men only, but other studies
have demonstrated lower serum ApoA1 in nephropathic
subjects [31, 32] and even more marked reductions in
interstitial fluid ApoA1 levels in type 1 diabetic subjects
with nephropathy [33]. No association of Lp(a) with ne-
phropathy was found. Previous small cross-sectional
studies in diabetic subjects have reported either increased
or unchanged Lp(a) levels with increased AER [34–37].
In a retrospective longitudinal study of subjects with
diabetes, Lp(a) levels increased with rising AER [38].
In previous DCCT-based studies of Lp(a), lower Lp(a)
levels were noted in the intensive versus conventional
management groups, but no difference according to AER
was found [6, 34]. Due to the wide range of serum Lp(a)
and the major influence of Lp(a) genotype on serum Lp(a),
cross-sectional studies require large numbers of subjects
per group and also benefit from Lp(a) genotype or phe-
notype analysis [39], which reflects particle size and per-
haps function. Lp(a) particle size has been more strongly
related to progression of carotid atherosclerosis [40] and
to survival in end-stage renal disease [41] than Lp(a)
level, but studies specifically in diabetes are lacking.
We were unable to find any association between LDL
“oxidizibility” and nephropathy. We previously demon-
strated that oxidizibility of LDL from 15 type 1 diabetic
patients with normal AER (and similar glycemic control
to the present study cohort) did not differ from oxidizibil-
ity in 15 matched nondiabetic controls [19]. Others have
found decreased resistance to oxidation of LDL from
subjects with end-stage renal disease compared with
healthy controls [42, 43], but this may be attributable to
the renal failure itself. To our knowledge there are no
published studies comparing LDL oxidizibility in sub-
jects with type 1 diabetes according to AER.
We also tested whether lipoprotein parameters were
associated with creatinine clearance, and obtained find-
ings broadly in agreement with those for AER. The
general agreement between the 2 measures of nephropa-
thy strengthens our conclusions.
Our study was cross-sectional, and could not address
the extent to which associated dyslipidemia is a cause
or an effect (or both or neither) of diabetic nephropathy.
However, our related study of retinopathy [abstract;
Lyons TJ et al, Diabetes 49(Suppl 1):1118P, 2000], an-
other microvascular complication, provides some cor-
roborative evidence. While it is known that renal func-
tion affects plasma lipoprotein profiles, it is less likely
that diabetic retinopathy does so as well. We found nu-
merous associations of the same lipoprotein parameters
with retinopathy status (controlling for nephropathy, gly-
cemia, and other pertinent variables) than in the present
study. This finding supports the possibility that dyslipide-
mia may contribute to, and not just result from, diabetic
microvascular disease. A retrospective longitudinal anal-
ysis of DCCT/EDIC samples including the NMR profiles
in stored pre-nephropathy samples is in progress, and
will clarify this important issue.
Longitudinal studies using conventional lipid profiles
also provide evidence in favor of a contributory role for
dyslipidemia in diabetic nephropathy [30, 44]. Mulec et al
[30] showed that total cholesterol, triglyceride, and apoB
were significant predictors of subsequent nephropathy.
Other evidence for a contributory role for lipoproteins in
diabetic nephropathy is found in studies demonstrating
amelioration of renal disease with intervention to im-
prove lipid profiles. Ellis et al [45] noted that a decrease
in LDL cholesterol is associated with regression of pro-
teinuria in subjects with type 1 diabetes. Treatment of
dyslipidemia by diet and/or drugs retards progression of
renal disease in type 1 and type 2 diabetic and nondia-
betic subjects [8, 44]. The Pittsburgh Epidemiology of
Diabetes Complications Study identified LDL choles-
terol and triglycerides as predictors of microalbuminuria,
observing significant gender differences in these associa-
tions [20]. Gender differences in each of the major lipo-
protein classes were also apparent in the current study.
They may be attributable to gender differences in the
“nephrotoxic” or “nephroprotective” effects of lipopro-
teins or lipoprotein-related factors. Lipoprotein subclass
distribution and HDL antioxidant activity is influenced
by several enzymes, including lipoprotein lipase, hepatic
lipase, lysolecithin cholesterol acyltransferase, choles-
terol ester transfer protein, and paraoxonase; activity
of these enzymes may be affected by hormone status.
Gender differences relating to insulin resistance may
also contribute to the observed differences in the NMR
profile between genders and subjects with and without
nephropathy; insulin resistance is known to be associated
with dyslipoproteinemia determined by NMR [46]. Other
aspects of lipoproteins and interactions with non-lipid
factors (such as C reactive protein), which we did not
assess in this analysis, may also contribute to the observed
gender differences in the lipoprotein-renal disease asso-
ciation.
Dyslipidemia may be both a cause and an effect of
renal disease. As this was a cross-sectional study we
could not separate the events, but the retrospective longi-
tudinal study in progress will provide further insight.
Potential contributors to dyslipidemia may be the trig-
gering of a generalized hepatic production of VLDL by
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albuminuria and its threat to plasma oncotic pressure.
Renal loss of apolipoproteins and other factors modulat-
ing lipoprotein metabolism and the effects of renal dys-
function on enzymes, which influence lipoprotein sub-
class distributions such as such as CETP and LCAT, may
also be contributory.
CONCLUSION
Our data show that in both women and men, a lipid
profile characterized by high triglycerides (predomi-
nantly in the smaller VLDL subclasses) is associated with
diabetic nephropathy. Furthermore, in men, high IDL,
high LDL particle concentration, and a shift from larger
toward smaller LDL, ApoB, and small (non-cardiopro-
tective) HDL levels are all associated with nephropathy.
This overall pattern, particularly in men, conforms to
the well-recognized atherogenic dyslipidemia character-
istic of insulin resistance and type 2 diabetes [9, 46].
Insulin resistance, central adiposity, and a positive family
history of type 2 diabetes may be associated with higher
nephropathy risk in type 1 diabetes [47]; in light of the
current data, the associated dyslipidemia may contribute.
Our findings are consistent with the existence of common
lipid-related risk factors for nephropathy and accelerated
atherosclerosis in diabetes. Since there may be differen-
tial effects of lipoprotein subclasses on nephropathy risk,
NMR lipoprotein analysis may prove a valuable means
to identify and monitor intervention in subjects at high
risk for complications, and may ultimately contribute to
reducing the morbidity and mortality associated with
type 1 diabetes.
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